Skip to Content
Merck
  • Non-invasive MR imaging of neurodegeneration in a rodent model of Parkinson's disease.

Non-invasive MR imaging of neurodegeneration in a rodent model of Parkinson's disease.

Methods in molecular biology (Clifton, N.J.) (2011-02-01)
Anthony C Vernon, Michel Modo
ABSTRACT

Neurotoxin-based rodent models of Parkinson's disease (PD) are widely used for pre-clinical evaluation of novel therapeutics for PD and have provided insights into mechanisms underlying motor dysfunction and nigrostriatal degeneration in PD. Predominantly, magnetic resonance imaging (MRI) studies in such models have focused on alterations in T(2) water (1)H relaxation or (1)H MR spectroscopy (MRS), whilst potential morphological changes and their relationship to histological or behavioural outcomes have not been fully investigated. Identification of MR signal changes that are significantly related to behavioural and histological outcomes in pre-clinical PD models may identify useful non-invasive surrogate markers of nigrostriatal degeneration in vivo. Development of such in vivo imaging-based biomarkers may provide a simple, efficient and comprehensive means to study lesion progression and therapeutic interventions in rodent models of PD, which may also have translational value.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lactacystin, ≥90% (HPLC)
Sigma-Aldrich
R-(−)-Apomorphine hydrochloride hemihydrate, calcined, ≥98.5% (with NaOH, titration)
Sigma-Aldrich
Anti-NeuN Antibody, clone A60, clone A60, Chemicon®, from mouse